Bioton SA operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bioton SA with three other
pharmaceutical manufacturers in Europe:
sales of 396.82 million Romanian Leu [US$98.03 million]
Cathay International Holdings Limited
of the United Kingdom
(£79.27 million [US$104.17 million]
of which 77%
was Lansen Group), and
Sinclair Pharma PLC
based in the United Kingdom
(£75.89 million [US$99.72 million]
of which 52%
was Direct (Country Opr)).
During the year ended December of 2015, sales at
Bioton SA were 404.41 million Polish New Zlotys (US$102.00 million).
increase of 7.2%
versus 2014, when the company's sales were 377.30 million Polish New Zlotys.
The sales level in 2015 was fairly close to the level five years ago: in 2010, Bioton SA had sales
of 378.60 million Polish New Zlotys.
Sales of Fisiopharma saw an increase
that was more than double the company's growth rate: sales were up
217.5% in 2015, from
22.63 million Polish New Zlotys to 71.85 million Polish New Zlotys.
Bioton SA also saw significant increases in sales in
Scigen Group (up 18.2% to 86.63 million Polish New Zlotys)
Not all segments of Bioton SA experienced an increase in sales in 2015:
sales of Biolek fell 92.7% to 40,000.00 Polish New Zlotys.
(However, this segment's sales were only a very small portion of the company's overall sales).
Bioton SA also experienced decreases in sales in
Mj Biopharm (down 8.4% to 62.30 million Polish New Zlotys)